Search

Your search keyword '"Simon Ramseier"' showing total 2 results
Start Over Author "Simon Ramseier"
2 results on '"Simon Ramseier"'

1. The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.

Author

Giulio Disanto, Pascal Benkert, Johannes Lorscheider, Stefanie Mueller, Jochen Vehoff, Chiara Zecca, Simon Ramseier, Lutz Achtnichts, Oliver Findling, Krassen Nedeltchev, Ernst-Wilhelm Radue, Till Sprenger, Christoph Stippich, Tobias Derfuss, Jean-François Louvion, Christian P Kamm, Heinrich P Mattle, Christoph Lotter, Renaud Du Pasquier, Myriam Schluep, Caroline Pot, Patrice H Lalive, Özgür Yaldizli, Claudio Gobbi, Ludwig Kappos, Jens Kuhle, and SMSC Scientific Board

Subjects
Medicine, Science
Abstract

The mechanisms leading to disability and the long-term efficacy and safety of disease modifying drugs (DMDs) in multiple sclerosis (MS) are unclear. We aimed at building a prospective cohort of MS patients with standardized collection of demographic, clinical, MRI data and body fluids that can be used to develop prognostic indicators and biomarkers of disease evolution and therapeutic response. The Swiss MS Cohort (SMSC) is a prospective observational study performed across seven Swiss MS centers including patients with MS, clinically isolated syndrome (CIS), radiologically isolated syndrome or neuromyelitis optica. Neurological and radiological assessments and biological samples are collected every 6-12 months. We recruited 872 patients (clinically isolated syndrome [CIS] 5.5%, relapsing-remitting MS [RRMS] 85.8%, primary progressive MS [PPMS] 3.5%, secondary progressive MS [SPMS] 5.2%) between June 2012 and July 2015. We performed 2,286 visits (median follow-up 398 days) and collected 2,274 serum, plasma and blood samples, 152 cerebrospinal fluid samples and 1,276 brain MRI scans. 158 relapses occurred and expanded disability status scale (EDSS) scores increased in PPMS, SPMS and RRMS patients experiencing relapses. Most RRMS patients were treated with fingolimod (33.4%), natalizumab (24.5%) or injectable DMDs (13.6%). The SMSC will provide relevant information regarding DMDs efficacy and safety and will serve as a comprehensive infrastructure available for nested research projects.

Published
2016
Full Text
View/download PDF

2. The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options

Author

Ludwig Kappos, Till Sprenger, Jens Kuhle, Johannes Lorscheider, Krassen Nedeltchev, Simon Ramseier, Oliver Findling, Ernst-Wilhelm Radue, Jean-François Louvion, Myriam Schluep, Giulio Disanto, Lutz Achtnichts, Renaud Du Pasquier, Claudio Gobbi, Christoph Stippich, Heinrich Mattle, Jochen Vehoff, Patrice H. Lalive, Pascal Benkert, Chiara Zecca, Christoph Lotter, Özgür Yaldizli, Smsc Scientific Board, Tobias Derfuss, Caroline Pot, Christian P. Kamm, Stefanie Karin Mueller, SMSC Scientific, Board, Ramseier, S., Achtnichts, L., Findling, O., Saxer, J., Nedeltchev, K., Remonda, L., Boxheimer, L., Kuhle, J., Kappos, L., Yaldizli£££Özguer£££ Ö., Derfuss, T., Sprenger, T., Limberg, M., Scheerer, I., Orleth, A., Treppke, F., Beregi, E., Stippich, C., Reinhardt, J., Fellner, I., Würfel, J., Radue, EW., Thoeni, A., Palatini, A., Pauli-Magnus, C., Fabbro, T., Benkert, P., Roesler, A., Mechati, S., Louvion, JF., Kamm, C., Chan, A., Mattle, H., Salmen, A., Kaeser, M., Wagner, F., Verma, R., Lalive, P., Di Marco, M., Haller, S., Lovblad, KO., Du Pasquier, R., Schluep, M., Pot, C., Granziera, C., Hagmann, P., Maeder, P., Gobbi, C., Zecca, C., Disanto, G., Tschuor, S., Cianfoni, A., Müller, S., Vehoff, J., Weber, J., and Lotter, C.

Subjects
Male, 0301 basic medicine, Physiology, Adult, Biomarkers/blood, Biomarkers/cerebrospinal fluid, Brain/radiography, Cohort Studies, Demography, Female, Fingolimod Hydrochloride/therapeutic use, Follow-Up Studies, Humans, Immunosuppressive Agents/therapeutic use, Magnetic Resonance Imaging, Middle Aged, Multiple Sclerosis/diagnosis, Multiple Sclerosis/drug therapy, Natalizumab/therapeutic use, Prognosis, Prospective Studies, Recurrence, Switzerland, lcsh:Medicine, ddc:616.07, Nervous System, Diagnostic Radiology, Geographical Locations, 0302 clinical medicine, Natalizumab, Medicine and Health Sciences, Medicine, 10. No inequality, Prospective cohort study, lcsh:Science, Cerebrospinal Fluid, Multidisciplinary, Clinically isolated syndrome, Radiology and Imaging, Brain, Neurodegenerative Diseases, Fingolimod, Body Fluids, 3. Good health, Europe, Neurology, Research Design, Cohort, Observational Studies, Anatomy, Immunosuppressive Agents, Research Article, medicine.drug, Cohort study, medicine.medical_specialty, Multiple Sclerosis, Imaging Techniques, Immunology, Research and Analysis Methods, Autoimmune Diseases, 03 medical and health sciences, Diagnostic Medicine, Internal medicine, Expanded Disability Status Scale, Fingolimod Hydrochloride, business.industry, Multiple sclerosis, lcsh:R, Biology and Life Sciences, medicine.disease, Demyelinating Disorders, Long-Term Care, Surgery, Health Care, Radiography, 030104 developmental biology, People and Places, Clinical Immunology, lcsh:Q, Clinical Medicine, business, Biomarkers, 030217 neurology & neurosurgery
Abstract

The mechanisms leading to disability and the long-term efficacy and safety of disease modifying drugs (DMDs) in multiple sclerosis (MS) are unclear. We aimed at building a prospective cohort of MS patients with standardized collection of demographic, clinical, MRI data and body fluids that can be used to develop prognostic indicators and biomarkers of disease evolution and therapeutic response. The Swiss MS Cohort (SMSC) is a prospective observational study performed across seven Swiss MS centers including patients with MS, clinically isolated syndrome (CIS), radiologically isolated syndrome or neuromyelitis optica. Neurological and radiological assessments and biological samples are collected every 6-12 months. We recruited 872 patients (clinically isolated syndrome [CIS] 5.5%, relapsing-remitting MS [RRMS] 85.8%, primary progressive MS [PPMS] 3.5%, secondary progressive MS [SPMS] 5.2%) between June 2012 and July 2015. We performed 2,286 visits (median follow-up 398 days) and collected 2,274 serum, plasma and blood samples, 152 cerebrospinal fluid samples and 1,276 brain MRI scans. 158 relapses occurred and expanded disability status scale (EDSS) scores increased in PPMS, SPMS and RRMS patients experiencing relapses. Most RRMS patients were treated with fingolimod (33.4%), natalizumab (24.5%) or injectable DMDs (13.6%). The SMSC will provide relevant information regarding DMDs efficacy and safety and will serve as a comprehensive infrastructure available for nested research projects.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results